Liquid Biopsy Testing for Cancer: ctDNA, CTC & RGCC

Liquid Biopsy Testing for Cancer: ctDNA, CTC & RGCC

Most cancer patients are familiar with the “wait and scan” model; PET or CT scans every few months, followed by anxious results. But what if there were blood-based tests that could detect cancer activity earlier, guide treatment decisions, and reduce unnecessary radiation exposure?

In this episode, we speak with Dr. Gez Agolli, integrative practitioner and medical director at Progressive Medical, about the evolving role of liquid biopsies in cancer care.

Together, we explore:

• What a liquid biopsy is and how it works
• The difference between ctDNA tests and circulating tumor cell (CTC) tests
• How the RGCC test helps identify which conventional, repurposed, or natural therapies may work best for a specific patient
• Why monitoring between scans matters, and how these tests can provide peace of mind
• The role of gut health, inflammation, and oxidative stress markers in cancer risk and progression
• Practical considerations: timing tests after chemotherapy, costs, and insurance coverage

Dr. Agolli emphasizes a proactive, precision-based approach: “If you don’t test, you just guess.”

Whether you’re newly diagnosed, in remission, or navigating follow-up care, this episode offers a grounded look at diagnostic tools that can help patients and practitioners make more informed decisions.

👉 Need help exploring testing or treatment options? Visit HealNavigator.com to connect with our team.

 

#LiquidBiopsy #ctDNA #RGCC #IntegrativeOncology #AlternativeCancerCare